Advances in sensor technologies and AI integration ... offering rapid and accurate results, multi-language support, and connectivity options. In February 2024, United States-based DexCom, Inc., a ...

This World Diabetes Day, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging ...

We recently published a list of 12 High Growth Large Cap Stocks to Buy Now. In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other high growth large ...

DexCom, Inc. DXCM reported third-quarter 2024 ... The broader S&P 500 index has moved up 21.6% in the same period. Sensor and other revenues (96% of total revenues) increased 9% on a year-over ...

Every study in these AID systems has been done with the DexCom sensor. So there aren't any head-to-head studies. They've all been run with DexCom, at least with our pump partners, and that's the ...

DexCom concluded the third quarter of 2024 on a positive note, with earnings and revenues surpassing expectations. Key drivers included significant contributions from the Sensor segment and robust ...

Mike Kratky, an analyst from Leerink Partners, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target was lowered to $87.00. Mike Kratky’s rating is based on ...

the company reported that it has submitted a 15-day version of its G7 sensor to the FDA for review. Currently, the device can be worn for up to 10 days among users as young as 2 years old. Dexcom ...

DexCom, Inc. DXCM is scheduled to release third ... Potential robust contributions from the Sensor segment, and domestic and international revenue growth are likely to have been the key catalysts ...

While there is some optimism around Dexcom’s efforts to rebuild the Durable Medical Equipment (DME) channel and the filing of the 15-day G-Series sensor with the FDA, the softer US performance ...